Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis

Cell Reports

Volumn 9, Issue 4, 2014, Pages 1333-1348

  Chatterjee, Anindya ^a   Ghosh, Joydeep ^a   Ramdas, Baskar ^a   Mali, Raghuveer Singh ^a   Martin, Holly ^a   Kobayashi, Michihiro ^a   Vemula, Sasidhar ^a   Canela, Victor H ^a   Waskow, Emily R ^a   Visconte, Valeria ^b   Tiu, Ramon V ^b   Smith, Catherine C ^c   Shah, Neil ^c   Bunting, Kevin D ^d   Boswell, H Scott ^a   Liu, Yan ^a   Chan, Rebecca J ^a   Kapur, Reuben ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FOCAL ADHESION KINASE; P21 ACTIVATED KINASE 1; RAC1 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MUTANT PROTEIN; P21 ACTIVATED KINASE; PROTEIN KINASE INHIBITOR; QUIZARTINIB; STEM CELL FACTOR RECEPTOR; TIAM1 PROTEIN, MOUSE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE MUTATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMOGENESIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOGENESIS; CELL NUCLEUS; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; SURVIVAL; SYSTEMIC MASTOCYTOSIS;

ANIMALS; BENZOTHIAZOLES; CARCINOGENESIS; CELL NUCLEUS; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MASTOCYTOSIS, SYSTEMIC; MICE, INBRED C57BL; MUTANT PROTEINS; MUTATION; P21-ACTIVATED KINASES; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-KIT; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS;

EID: 84912133309     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.10.039     Document Type: Article

References (49)

1. Aksamitiene E., Achanta S., Kolch W., Kholodenko B.N., Hoek J.B., Kiyatkin A. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell. Signal. 2011, 23:1794-1805.
2. Barros P., Lam E.W., Jordan P., Matos P. Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters. Nucleic Acids Res. 2012, 40:7776-7787.
3. Baumgartner C., Cerny-Reiterer S., Sonneck K., Mayerhofer M., Gleixner K.V., Fritz R., Kerenyi M., Boudot C., Gouilleux F., Kornfeld J.W., et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am. J. Pathol. 2009, 175:2416-2429.
4. Beghini A., Ripamonti C.B., Cairoli R., Cazzaniga G., Colapietro P., Elice F., Nadali G., Grillo G., Haas O.A., Biondi A., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89:920-925.
5. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954.
6. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J.Biol. Chem. 2000, 275:1829-1838.
7. Brady A., Gibson S., Rybicki L., Hsi E., Saunthararajah Y., Sekeres M.A., Tiu R., Copelan E., Kalaycio M., Sobecks R., et al. Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia. Eur. J. Haematol. 2012, 89:288-293.
8. Buongiorno P., Pethe V.V., Charames G.S., Esufali S., Bapat B. Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells. Mol. Cancer 2008, 7:73.
9. Butterfield J.H., Weiler D., Dewald G., Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 1988, 12:345-355.
10. Chang F., Lemmon C.A., Park D., Romer L.H. FAK potentiates Rac1 activation and localization to matrix adhesion sites: a role for betaPIX. Mol. Biol. Cell 2007, 18:253-264.
11. Choudhary C., Müller-Tidow C., Berdel W.E., Serve H. Signal transduction of oncogenic Flt3. Int. J. Hematol. 2005, 82:93-99.
12. Choudhary C., Brandts C., Schwable J., Tickenbrock L., Sargin B., Ueker A., Böhmer F.D., Berdel W.E., Müller-Tidow C., Serve H. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007, 110:370-374.
13. Deacon S.W., Beeser A., Fukui J.A., Rennefahrt U.E., Myers C., Chernoff J., Peterson J.R. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 2008, 15:322-331.
14. Despeaux M., Labat E., Gadelorge M., Prade N., Bertrand J., Demur C., Recher C., Bonnevialle P., Payrastre B., Bourin P., Racaud-Sultan C. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia 2011, 25:1789-1793.
15. Elias B.C., Bhattacharya S., Ray R.M., Johnson L.R. Polyamine-dependent activation of Rac1 is stimulated by focal adhesion-mediated Tiam1 activation. Cell Adhes. Migr. 2010, 4:419-430.
16. Gabarra-Niecko V., Schaller M.D., Dunty J.M. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003, 22:359-374.
17. Golubovskaya V.M., Nyberg C., Zheng M., Kweh F., Magis A., Ostrov D., Cance W.G. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J.Med. Chem. 2008, 51:7405-7416.
18. Golubovskaya V.M., Figel S., Ho B.T., Johnson C.P., Yemma M., Huang G., Zheng M., Nyberg C., Magis A., Ostrov D.A., et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth invivo. Carcinogenesis 2012, 33:1004-1013.
19. Hartman A.D., Wilson-Weekes A., Suvannasankha A., Burgess G.S., Phillips C.A., Hincher K.J., Cripe L.D., Boswell H.S. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. Exp. Hematol. 2006, 34:1360-1376.
20. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000, 19:624-631.
21. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555-2563.
22. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., Walker H., Wheatley K., Bowen D.T., Burnett A.K., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
23. Lange B., Valtieri M., Santoli D., Caracciolo D., Mavilio F., Gemperlein I., Griffin C., Emanuel B., Finan J., Nowell P., et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987, 70:192-199.
24. Li S., Hua Z.C. FAK expression regulation and therapeutic potential. Adv. Cancer Res. 2008, 101:45-61.
25. Li L., Piloto O., Kim K.T., Ye Z., Nguyen H.B., Yu X., Levis M., Cheng L., Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br. J. Haematol. 2007, 137:64-75.
26. Lu J., Sun Y., Nombela-Arrieta C., Du K.P., Park S.Y., Chai L., Walkley C., Luo H.R., Silberstein L.E. Fak depletion in both hematopoietic and nonhematopoietic niche cells leads to hematopoietic stem cell expansion. Exp. Hematol. 2012, 40:307-317.e3.
27. Mali R.S., Ramdas B., Ma P., Shi J., Munugalavadla V., Sims E., Wei L., Vemula S., Nabinger S.C., Goodwin C.B., et al. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 2011, 20:357-369.
28. Martin H., Mali R.S., Ma P., Chatterjee A., Ramdas B., Sims E., Munugalavadla V., Ghosh J., Mattingly R.R., Visconte V., et al. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J.Clin. Invest. 2013, 123:4449-4463.
29. McDaniel A.S., Allen J.D., Park S.J., Jaffer Z.M., Michels E.G., Burgin S.J., Chen S., Bessler W.K., Hofmann C., Ingram D.A., et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 2008, 112:4646-4654.
30. Murray B.W., Guo C., Piraino J., Westwick J.K., Zhang C., Lamerdin J., Dagostino E., Knighton D., Loi C.M., Zager M., et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. USA 2010, 107:9446-9451.
31. Nyga R., Pecquet C., Harir N., Gu H., Dhennin-Duthille I., Régnier A., Gouilleux-Gruart V., Lassoued K., Gouilleux F. Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter. Biochem. J. 2005, 390:359-366.
32. Obermann E.C., Arber C., Jotterand M., Tichelli A., Hirschmann P., Tzankov A. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann. Hematol. 2010, 89:663-669.
33. Pelletier S., Duhamel F., Coulombe P., Popoff M.R., Meloche S. Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors. Mol. Cell. Biol. 2003, 23:1316-1333.
34. Recher C., Ysebaert L., Beyne-Rauzy O., Mansat-De Mas V., Ruidavets J.B., Cariven P., Demur C., Payrastre B., Laurent G., Racaud-Sultan C. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 2004, 64:3191-3197.
35. Rocnik J.L., Okabe R., Yu J.C., Lee B.H., Giese N., Schenkein D.P., Gilliland D.G. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 2006, 108:1339-1345.
36. Sallmyr A., Fan J., Datta K., Kim K.T., Grosu D., Shapiro P., Small D., Rassool F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood 2008, 111:3173-3182.
37. Schmidt A., Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002, 16:1587-1609.
38. Schürmann A., Mooney A.F., Sanders L.C., Sells M.A., Wang H.G., Reed J.C., Bokoch G.M. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol. 2000, 20:453-461.
39. Simon A.R., Vikis H.G., Stewart S., Fanburg B.L., Cochran B.H., Guan K.L. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000, 290:144-147.
40. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., Perl A.E., Travers K.J., Wang S., Hunt J.P., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
41. Spiekermann K., Bagrintseva K., Schwab R., Schmieja K., Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 2003, 9:2140-2150.
42. Traina F., Visconte V., Jankowska A.M., Makishima H., O'Keefe C.L., Elson P., Han Y., Hsieh F.H., Sekeres M.A., Mali R.S., et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE 2012, 7:e43090.
43. Tse K.F., Mukherjee G., Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000, 14:1766-1776.
44. Vemula S., Ramdas B., Hanneman P., Martin J., Beggs H.E., Kapur R. Essential role for focal adhesion kinase in regulating stress hematopoiesis. Blood 2010, 116:4103-4115.
45. Ye D.Z., Field J. PAK signaling in cancer. Cell. Logist. 2012, 2:105-116.
46. Yin B. Focal adhesion kinase as a target in the treatment of hematological malignancies. Leuk. Res. 2011, 35:1416-1418.
47. Zhang S., Fukuda S., Lee Y., Hangoc G., Cooper S., Spolski R., Leonard W.J., Broxmeyer H.E. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J.Exp. Med. 2000, 192:719-728.
48. Zhao J., Guan J.L. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009, 28:35-49.
49. Zheng R., Bailey E., Nguyen B., Yang X., Piloto O., Levis M., Small D. Further activation of FLT3 mutants by FLT3 ligand. Oncogene 2011, 30:4004-4014.